Role of Stereotactic Ablative Radiotherapy in Early-Stage Lung Cancer

Video

This video examines the role of radiation therapy in early-stage lung cancer and some of the data comparing stereotactic ablative radiotherapy vs surgery in these patients.

In this video Alexander Louie, MD, PhD, MSc, of the London Health Sciences Centre in Canada, discusses the role of stereotactic ablative radiotherapy (SABR) in early-stage lung cancer patients who are not eligible for surgery, some of the literature about late effects of radiotherapy, and data comparing SABR vs surgery.

Louie gave a presentation on this topic at the 2017 Multidisciplinary Thoracic Cancers Symposium.

Recent Videos
Advancements in antibody drug conjugates, bispecific therapies, and other targeted agents may hold promise in lung cancer management.
Stressing the importance of prompt AE disclosure before they become severe can ensure that a patient can still undergo resection with curative intent.
Thomas Marron, MD, PhD, presented a session on clinical data that established standards of care for stage II and III lung cancer treatment at CFS 2025.
Decreasing the low-dose bath of proton therapy to the body may limit the impact of radiation on lymphocytes and affect tumor response.
According to Eyub Akdemir, MD, reducing EDIC may be feasible without compromising target coverage to reduce anticipated lymphopenia rates.
According to Jorge Nieva, MD, there are a multitude of things that can be explored to enhance the treatment landscape for lung cancer.
In a CancerNetwork® YouTube video, Cornelia Tischmacher, a mother of twins from Germany, outlined her receipt of double lung transplantation.
Ongoing ctDNA analysis may elucidate outcomes associated with divarasib plus migoprotafib for those with KRAS G12C–positive NSCLC.
Related Content
Data from the DeLLphi-304 trial support the full approval of tarlatamab in this extensive-stage small cell lung cancer population.

Tarlatamab Earns Traditional FDA Approval in ES-SCLC

Russ Conroy
November 19th 2025
Article

Data from the DeLLphi-304 trial support the full approval of tarlatamab in this extensive-stage small cell lung cancer population.

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

What Were the Key Presentations at ESMO 2025? Oncology Experts Discuss

Sara A. Hurvitz, MD;Xiuning Le, MD, PhD;Erica L. Mayer, MD, MPH
October 27th 2025
Podcast

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

Data from a phase 1a/1b trial show that no patients discontinued STK-012 due to treatment-related adverse effects.

Novel IL-2 Therapy Combo Yields Initial Responses in Nonsquamous NSCLC

Russ Conroy
November 8th 2025
Article

Data from a phase 1a/1b trial show that no patients discontinued STK-012 due to treatment-related adverse effects.

Georgios Evangelou, MD, MSc, speaks to the potential utility of neoadjuvant capecitabine/temozolomide in well-differentiated atypical carcinoids.

Exploring the Value of Preoperative CAPTEM in Atypical Lung NETs

Georgios Evangelou, MD, MSc
September 16th 2024
Podcast

Georgios Evangelou, MD, MSc, speaks to the potential utility of neoadjuvant capecitabine/temozolomide in well-differentiated atypical carcinoids.

ILKN421H plus pembrolizumab previously showed antitumor activity among patients with frontline non–small cell lung cancer in a phase 1 trial.

FDA Clears IND Application for Novel IL-2 Agent in Advanced NSCLC

Russ Conroy
November 4th 2025
Article

ILKN421H plus pembrolizumab previously showed antitumor activity among patients with frontline non–small cell lung cancer in a phase 1 trial.

Data from the phase 2 TUXEDO-3 trial support patritumab deruxtecan as a novel treatment option across different cancer populations with brain metastases.

HER3-DXd Yields Activity in NSCLC, Breast Cancer Brain Metastasis Groups

Russ Conroy
October 31st 2025
Article

Data from the phase 2 TUXEDO-3 trial support patritumab deruxtecan as a novel treatment option across different cancer populations with brain metastases.